Let’s take a look at why Onconova Therapeutics, Inc. (ONTX) surged in the Postmarket hours

Onconova Therapeutics, Inc. (NASDAQ: ONTX), shares rose above 37% to 0.586 in the post-‎market session today after the news that it has earned the U.S. Food and Drug ‎Administration (FDA) clearance for a Phase 1 analysis to continue with ON 123300, a ‎proprietary, differentiated, first-in-class multi-kinase inhibitor, under the Company’s ‎Investigational New Drug Application (IND).‎

Get ‎the hottest stocks to trade every day before the market opens 100% ‎free. Click here ‎now. 

‎The Phase 1 study will be performed in the United States and will test the efficacy, safety ‎profile, and pharmacokinetics of orally administered ON 123300 as monotherapy at ‎elevated doses beginning at or beyond 40 mg daily for 28 consecutive days. Patients with ‎relapsed/refractory advanced cancer, including but not limited to HR+ HER2-metastatic ‎breast cancer patients with clinical resistance to licensed second-generation CDK4/6 ‎inhibitors, will be included in the study. Once the dose escalation step of the trial is finished ‎and the recommended Phase 2 dose is identified, additional HR+ HER2- postmenopausal ‎metastatic breast cancer patients immune to licensed second-generation CDK4/6 inhibitors ‎will be enrolled. Additional patient cohorts, including but not limited to patients diagnosed ‎with advanced colorectal cancer, and non-lymphoma, Hodgkin’s particularly mantle cell ‎lymphoma, are under consideration.‎

Discover Tomorrow's Stocks Today!

When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.

Claim the free report now by clicking here and start discovering the hidden gems of the market

Read More

The development of this U.S. The phase 1 experiment varies from the ongoing research ‎performed in China with ON 123300 by HanX Biopharmaceuticals, Inc., a partner of the ‎firm, which doses patients for 21 days every day. To date, four patients have been enrolled ‎in the HanX study, the second dosing cohort has been opened, and it is expected that ‎patients with advanced cancer will continue to be enrolled at two sites before the ‎recommended Phase 2 dose is identified. Notably, of the three currently approved inhibitors ‎of CDK4/6, two are approved for 21-day cycle dosing and one is approved for 28-day cycle ‎dosing. All three are blockbuster treatments sold by well-known pharmaceutical firms for ‎HR+ HER2-metastatic breast cancer, and all of these licensed therapies include concomitant ‎therapy with an aromatase inhibitor.‎

Most Popular

Related posts